Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully; Deepak Singh; Robert Lown; Anthony Poles; Tom Solomon; Marcel Levi; David Goldblatt; Pavel Kotouček; William D. Thomas; Will Lester

doi:10.1056/nejmoa2105385

Abstract

Vaccination against SARS-CoV-2 remains critical for control of the Covid-19 pandemic. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, can occur after the administration of the ChAdOx1 nCoV-19 vaccine. Rapid identification of this rare syndrome is important because of the therapeutic implications.

Keywords

MedicineVaccinationThrombosisImmunologyAdverse effectThrombophiliaAntibodyFibrinogenInternal medicinePandemicVenous thrombosisDiseaseCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)

Affiliated Institutions

Related Publications

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher , Thomas Thiele , Theodore E. Warkentin +3 more

Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinicall...

2021 New England Journal of Medicine 2213 citations

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina Haagenrud Schultz , Ingvild Hausberg Sørvoll , Annika E. Michelsen +8 more

We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vecto...

2021 New England Journal of Medicine 1471 citations

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Aliasgar Esmail , Marisa Groenewald , Elizea Horne +48 more

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Fou...

2021 New England Journal of Medicine 1301 citations

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Hanny Al‐Samkari , Rebecca S. Karp Leaf , Sunny Dzik +10 more

Abstract Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular ...

2020 Blood 1376 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Wendy E.M. Crocker , Christina J. Cunningham , Pedro M. Folegatti +97 more

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a v...

2020 The Lancet 2590 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 23
Pages: 2202-2211
Citations: 976
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

976

OpenAlex

Cite This

APA Style

                            
                                
                                    Marie Scully, 
                                
                                    Deepak Singh, 
                                
                                    Robert Lown
                                
                                et al.
                            
                            (2021). 
                            Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. 
                            New England Journal of Medicine
                            , 384
                            (23)
                            , 2202-2211.
                            https://doi.org/10.1056/nejmoa2105385
                        

Identifiers

DOI: 10.1056/nejmoa2105385